Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
The tumour suppressor FBW7 is the substrate recognition component of the SCF-type ubiquitin ligase that degrades several proto-oncogenes, including MYC and cyclin E. How do the numerous cancer-associated mutations inFBW7and its substrates contribute to tumorigenesis?
Tumour responses to treatment are still largely assessed from imaging measurements of reductions in tumour size, which can take weeks to be manifest. This Review presents the new non-invasive techniques that can give early evidence of tumour response.
DNA vaccines against cancer allow a high degree of molecular precision, but until recently translation into the clinic has been difficult. Advances in delivery techniques are now allowing them to fulfil their potential.
Cancer cells survive despite violating rules that ordinarily provoke apoptosis. Now that we understand more about how members of the BCL2 family of proteins regulate apoptosis, can we exploit our knowledge to more effectively target cancer cells?
The Ras-family G-proteins RALA and RALB seem to be key offenders in the subversion of core biological systems driving oncogenic transformation. This up-to-date Review focuses on current developments within this field.
This Perspective provides an intriguing look at cell competition, which was originally described inDrosophila melanogastermore than 30 years ago. How do cells compete with one another, and how might this process relate to cancer?
Naturally occurring cancers in pet dogs are similar to those in humans, and there is a growing interest in using studies in dogs to complement research in humans and mice. How can the study of pet dogs contribute to the development of new cancer therapeutics?
